(Q39363811)

11 September 2017

title

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers (English)

1 reference

11 September 2017

0 references

0 references

10

Yung-Jue Bang

1 reference

11 September 2017

9

Seock-Ah Im

1 reference

11 September 2017

8

Do-Youn Oh

1 reference

11 September 2017

7

Sae-Won Han

1 reference

11 September 2017

11

Tae-You Kim

1 reference

11 September 2017

4

Hwang-Phill Kim

1 reference

11 September 2017

5

Young-Kwang Yoon

1 reference

11 September 2017

2

Sang-Hyun Song

1 reference

11 September 2017

6

Kyung-Hun Lee

1 reference

11 September 2017

Jiyeon Yun

1

1 reference

11 September 2017

Jinah Park

series ordinal

3

1 reference

11 September 2017

publication date

16 April 2012

1 reference

11 September 2017

published in

Laboratory Investigation

1 reference

11 September 2017

volume

92

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1033-1044

1 reference

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Aberrant methylation of integrin alpha4 gene in human gastric cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

A genome-wide study of DNA methylation patterns and gene expression levels in multiple human and chimpanzee tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epigenetic aberrations during oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Multiple functions of Ldb1 required for beta-globin activation during erythroid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

EUKARYOTIC CYTOSINE METHYLTRANSFERASES

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNA motifs associated with aberrant CpG island methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epiregulin promotes proliferation and migration of renal proximal tubular cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

New nucleoside analogs for patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

inferred from DOI database lookup

7 January 2021

based on heuristic

Epigenetics and human disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

inferred from DOI database lookup

7 January 2021

based on heuristic

Rash conclusions from a phase 3 study of cetuximab?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.61

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LABINVEST.2012.61

1 reference

11 September 2017

1 reference